Encouraging words from the CEO of IPSENMarc de Garidel, Chairman and Chief Executive Officer of Ipsen stated: “Ipsen is pleased to enter into a partnership with Telesta Therapeutics for Europe and key Rest of the World territories. We believe MCNA, which received priority review from FDA, is a promising second line bladder cancer treatment that would perfectly fit our urology-oncology portfolio in Europe.” Marc de Garidel added: “This licensing agreement fits our business development strategy, focusing on selected niche therapeutic areas”.
https://www.ipsen.com/wp-content/uploads/2015/10/10-28-2015-PR-Ipsen-Telesta-MCNA-bladder-FINAL.pdf
The other promissing thing in this document is the following:
Their extensive knowledge of the regulatory and commercial landscape, their commercial presence in more than 100 countries across the globe, as well as their commitment to their core urology franchise, particularly bladder cancer, is why we are convinced that they will successfully bring MCNA to urologists and their patients, outside of the United States, and generate significant value for Telesta’s shareholders.”
While I am sure obtaining a positive result from the FDA will help in other jurisdiction, Ipsen has the experience and funds to move forward in these other jurisdictions without FDA approval. Hopefully, we can get positive news from other jurisdiction from this strong partnership! It would be interesting to know if those efforts are going on as we speak and could be announced any time now. That would be another potential catalyst.
DD